KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $10.2 million.

  • Sarepta Therapeutics' Other Accumulated Expenses fell 4077.74% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 4077.74%. This contributed to the annual value of $13.5 million for FY2024, which is 2449.99% down from last year.
  • Sarepta Therapeutics' Other Accumulated Expenses amounted to $10.2 million in Q3 2025, which was down 4077.74% from $10.4 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Other Accumulated Expenses ranged from a high of $26.2 million in Q3 2022 and a low of $5.3 million during Q4 2022
  • For the 5-year period, Sarepta Therapeutics' Other Accumulated Expenses averaged around $16.0 million, with its median value being $17.1 million (2024).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 6469.34% in 2022, then soared by 23581.11% in 2023.
  • Sarepta Therapeutics' Other Accumulated Expenses (Quarter) stood at $15.1 million in 2021, then crashed by 64.69% to $5.3 million in 2022, then surged by 235.81% to $17.8 million in 2023, then fell by 24.5% to $13.5 million in 2024, then decreased by 24.0% to $10.2 million in 2025.
  • Its Other Accumulated Expenses was $10.2 million in Q3 2025, compared to $10.4 million in Q2 2025 and $13.0 million in Q1 2025.